Heparin‐induced thrombocytopenia: pathogenesis and management

British Journal of Haematology - Tập 121 Số 4 - Trang 535-555 - 2003
Theodore E. Warkentin1
1Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton, Ontario, Canada

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1055/s-0038-1656329

10.1055/s-0038-1651670

10.1046/j.1365-2141.1996.407945.x

Amiral J., 1996, Presence of autoantibodies to interleukin‐8 or neutrophil‐activating peptide‐2 in patients with heparin‐associated thrombocytopenia, Blood, 88, 410, 10.1182/blood.V88.2.410.bloodjournal882410

10.1002/(SICI)1096-8652(199606)52:2<90::AID-AJH4>3.0.CO;2-0

10.1097/00001721-199703000-00005

10.1046/j.1365-2141.2000.02034.x

10.1016/S0003-4975(00)02022-1

10.1182/blood.V98.4.1252

10.1182/blood.V94.1.208.413a06_208_215

10.1016/S0198-8859(00)00242-1

10.1016/S0140-6736(94)90781-1

Carlsson L.E., 1998, Heparin‐induced thrombocytopenia: new insights into the impact of the FcγRIIa–R–H131 polymorphism, Blood, 92, 1526, 10.1182/blood.V92.5.1526

10.1055/s-0038-1651610

Chong B.H., 1994, Plasma P‐selectin is increased in thrombotic consumptive platelet disorders, Blood, 83, 1535, 10.1182/blood.V83.6.1535.1535

10.1055/s-0037-1616046

Denomme G.A., 2001, Heparin‐induced Thrombocytopenia, 189

10.1016/S0022-2143(97)90022-6

Eichler P., 1999, First workshop for detection of heparin‐ induced antibodies: validation of the heparin‐induced platelet activation (HIPA) test in comparison with a PF4/heparin ELISA, Thrombosis and Haemostasis, 81, 625, 10.1055/s-0037-1614536

Eichler P., 2000, Antihirudin antibodies in patients with heparin‐induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance, Blood, 96, 2373, 10.1182/blood.V96.7.2373

10.1046/j.0007-1048.2002.03363.x

Eichler P., 2002, Results of the third prospective study of treatment with lepirudin in patients with heparin‐induced thrombocytopenia (HAT), Blood, 100, 704a

10.1055/s-0037-1615946

10.1067/mob.2001.114690

Fischer K.G., 2001, Heparin‐induced Thrombocytopenia, 409

10.1016/S0003-4975(02)04349-7

Francis J.L. Drexler A. Gwyn G.&Moroose R.(2003b)Bivalirudin a direct thrombin inhibitor in the treatment of heparin‐induced thrombocytopenia.Journal of Thrombosis and Haemostasis(in press).

10.1182/blood-2002-07-2201

10.1111/j.1365-2141.1994.tb05120.x

10.1055/s-2007-1000384

Greinacher A., 2001, Heparin‐induced Thrombocytopenia, 291

10.1055/s-0038-1646493

10.1111/j.1365-2141.1992.tb08216.x

10.1111/j.1365-2141.1993.tb03150.x

Greinacher A., 1994, Heparin‐associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4–heparin complex as the major antigen, Thrombosis and Haemostasis, 71, 247

10.1046/j.1537-2995.1994.34594249047.x

Greinacher A., 1994, Heparin‐associated thrombocytopenia: the effects of various intravenous IgG preparations on antibody mediated platelet activation: a possible new indication of high dose i.v. IgG, Thrombosis and Haemostasis, 71, 641, 10.1055/s-0038-1642496

10.1161/01.CIR.99.1.73

10.1161/01.CIR.100.6.587

Greinacher A., 2000, Heparin‐induced thrombocytopenia with thromboembolic complications: meta‐analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range, Blood, 96, 846, 10.1182/blood.V96.3.846

10.1016/S0140-6736(94)91797-3

10.1378/chest.119.1_suppl.64S

Hong A.P. Cook D.J. Sigouin C.S.&Warkentin T.E.(2003)Central venous catheters and upper‐extremity deep‐vein thrombosis complicating immune heparin‐induced thrombocytopenia.Blood 101 3049–3051.

10.1002/(SICI)1096-8652(199805)58:1<24::AID-AJH5>3.0.CO;2-2

10.1182/blood.V96.1.188

10.1097/00000542-200102000-00013

10.1067/mtc.2001.118271

Kwaan H.C., 1999, Endothelial cell hyperplasia contributes to thrombosis in heparin‐induced thrombocytopenia, Seminars in Thrombosis and Hemostasis, 25, 23

Lee D.H., 2001, Heparin‐induced Thrombocytopenia, 87

10.1046/j.1365-2141.1996.d01-1944.x

Lee D.H., 1998, Factor V Leiden and thrombotic complications in heparin‐induced thrombocytopenia, Thrombosis and Haemostasis, 79, 50, 10.1055/s-0037-1614218

10.1111/j.1471-0528.2003.00272.x

10.1161/01.CIR.103.14.1838

10.1002/ccd.10276

Lewis B.E. Wallis D.E. Leya F. Hursting M.J.&Kelton J.G.(2003)Argatroban anticoagulation in patients with heparin‐induced thrombocytopenia.Archives of Internal Medicine(in press).

10.1182/blood.V99.4.1230

10.1046/j.1365-2141.2001.02869.x

10.1046/j.1365-2141.2002.03687.x

10.1097/00000542-199812000-00037

10.1016/S0049-3848(00)00311-X

10.1378/chest.122.1.37

Lubenow N., 2002, Results of a large drug monitoring program confirms the safety and efficacy of Refludan (lepirudin) in patients with immune‐mediated heparin‐induced thrombocytopenia, Blood, 100, 502a

Lubenow N., 2002, Meta‐analysis of three prospective studies of lepirudin in the prevention of thrombosis in patients with heparin‐induced thrombocytopenia, Blood, 100, 501a

McIntyre K., 2001, Heparin‐ induced Thrombocytopenia, 445

Magnani H.N., 1993, Heparin‐induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172), Thrombosis and Haemostasis, 70, 554, 10.1055/s-0038-1649626

Magnani H.N., 1997, New Anticoagulants for the Cardiovascular Patient, 487

10.1016/S0140-6736(99)03625-9

10.1046/j.1365-2141.1999.01717.x

Newman P.M., 2000, Heparin‐induced thrombocytopenia: new evidence for the dynamic binding of purified anti‐PF4–heparin antibodies to platelets and the resultant platelet activation, Blood, 96, 182, 10.1182/blood.V96.1.182

Newman P.M., 1998, Heparin‐induced thrombocytopenia: IgG binding to PF4–heparin complexes in the fluid phase and cross‐reactivity with low molecular weight heparin and heparinoid, Thrombosis and Haemostasis, 80, 292, 10.1055/s-0037-1615190

Poetzsch B., 2001, Heparin‐induced Thrombocytopenia, 429

Polgár J., 1998, Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera form heparin‐induced thrombocytopenia patients, Blood, 91, 549, 10.1182/blood.V91.2.549

10.1016/S0272-6386(97)90208-0

Pötzsch B., 1997, Monitoring of r‐hirudin anticoagulation during cardiopulmonary bypass assessment of the whole blood ecarin clotting time, Thrombosis and Haemostasis, 77, 920, 10.1055/s-0038-1656078

10.1056/NEJM200008173430718

10.1161/01.CIR.99.19.2530

10.1182/blood.V97.10.3300

Ranze O., 2000, The use of low‐molecular‐weight heparins in heparin‐induced thrombocytopenia (HIT): a cohort study, Annals of Hematology, 79, P198

10.1182/blood.V98.8.2442

10.7326/0003-4819-136-3-200202050-00009

10.1055/s-2001-15259

Sheth S.B., 2001, Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin, Thrombosis and Haemostasis, 85, 435, 10.1055/s-0037-1615601

10.1002/ajh.10181

Srinivasan A.F. Rice L. Bartholomew J.R. Rangaswamy C. La Perna L. Thompson J.E. Murphy S.&Baker K.R.(2003)Warfarin‐induced skin necrosis and venous limb gangrene in the setting of heparin‐induced thrombocytopenia.Archives of Internal Medicine(in press).

10.1002/(SICI)1096-8652(199703)54:3<196::AID-AJH4>3.0.CO;2-R

Suh J.S., 1998, Antibodies from patients with heparin‐induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4, Blood, 91, 916, 10.1182/blood.V91.3.916

Tardy B., 1999, Lower limb veins should be systematically explored in patients with isolated heparin‐induced thrombocytopenia, Thrombosis and Haemostasis, 82, 1199, 10.1055/s-0037-1614355

10.1172/JCI116987

10.1067/mlc.2001.115525

10.1016/S0002-9343(99)00124-2

10.1046/j.1365-2141.1996.d01-1481.x

10.1016/S0887-7963(96)80001-0

Warkentin T.E., 1996, Danaparoid (Orgaran) for the treatment of heparin‐induced thrombocytopenia (HIT) and thrombosis: effects on in vivo thrombin and cross‐linked fibrin generation, and evaluation of the clinical significance of in vitro cross‐reactivity (SR) of danaparoid for HIT‐IgG, Blood, 88, 626a

Warkentin T.E., 2001, Heparin‐induced Thrombocytopenia, 271

Warkentin T.E., 2001, Heparin‐induced Thrombocytopenia, 1

Warkentin T.E., 2001, Heparin‐induced Thrombocytopenia, 43

Warkentin T.E., 2001, Heparin‐induced thrombocytopenia: yet another treatment paradox?, Thrombosis and Haemostasis, 85, 947, 10.1055/s-0037-1615945

10.7326/0003-4819-135-8_Part_1-200110160-00009

Warkentin T.E., 2002, Platelet count monitoring and laboratory testing for heparin‐induced thrombocytopenia, Archives of Pathology and Laboratory Medicine, 126, 1415, 10.5858/2002-126-1415-PCMALT

Warkentin T.E., 2002, Heparin‐induced thrombocytopenia, Current Hematology Reports, 1, 63

Warkentin T.E., 2002, Heparin‐induced thrombocytopenia for the anesthesiologist, Canadian Journal of Anesthesia, 49, s36

Warkentin T.E., 2002, Heparin‐induced thrombocytopenia, part 2: clinical course and treatment, Journal of Critical Illness, 17, 215

Warkentin T.E.&Bernstein R.A.(2003)Delayed‐onset heparin‐induced thrombocytopenia and cerebral thrombosis following a single administration of unfractionated heparin.New England Journal of Medicine(in press).

Warkentin T.E., 2001, Heparin‐induced Thrombocytopenia, 231

10.1016/j.athoracsur.2003.09.034

Warkentin T.E.&Heddle N.M.(2003)Laboratory diagnosis of immune heparin‐induced thrombocytopenia.Current Hematology Reports 2 148–157.

10.1016/S0002-9343(96)00258-6

10.7326/0003-4819-135-7-200110020-00009

10.1056/NEJM200104263441704

10.1080/09537109975960

Warkentin T.E., 2002, Gender and risk of immune heparin‐induced thrombocytopenia, Blood, 100, 17a

Warkentin T.E., 1992, Determinants of donor platelet variability when testing for heparin‐induced thrombocytopenia, Journal of Laboratory and Clinical Medicine, 120, 371

10.1182/blood.V84.11.3691.bloodjournal84113691

10.1016/0002-9343(94)90332-8

10.1056/NEJM199505183322003

10.7326/0003-4819-127-9-199711010-00005

10.1055/s-0037-1614206

10.1002/(SICI)1096-8652(199909)62:1<44::AID-AJH7>3.0.CO;2-F

10.1182/blood.V96.5.1703

10.1016/S0003-4975(01)02583-8

10.1001/archinte.163.20.2518

10.1182/blood.V92.9.3250